Yixi Hu

Disclosure information not submitted.

Presentation(s):

• PD43-07: TKI-induced treatment resistance of RCC via modulating the long non-coding RNA-ECVSR/ER&[beta]/Hif2-&[alpha] signaling

  Sunday, May 15, 2022
  10:30 AM – 10:40 AM

• PD46-12: Preclinical studies using cisplatin/carboplatin to restore the Enzalutamide sensitivity via degrading the androgen receptor splicing variant 7 (ARv7) to further suppress Enzalutamide resistant prostate cancer

  Sunday, May 15, 2022
  2:50 PM – 3:00 PM